To the Editor: I would like to report incomplete financial disclosures related to an Editorial,1 a Clinical Crossroads article,2 and a subsequent reply to a letter to the editor3 published in JAMA. This resulted from my misinterpretation of JAMA requirements for reporting conflicts of interest. As I noted previously,1-3 I am on the board of directors of Gilead Sciences and a consultant for Chimerix; I receive compensation and stock from both companies. Neither company is involved in the development of drugs to treat herpesvirus infections. However, I did not report 3 financial disclosure issues.